Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - NeoTherapeutics, Inc. (NasdaqNM:NEOT)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Msgs | Insider
Location
157 Technology Drive
Irvine, CA 92618
Phone: (949) 788-6700
Fax: (949) 788-6706
Email: cgruetter@neotherapeutics.com
Employees (last reported count): 53
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 51%
·Over the last 6 months:
 · one insider buy; 3,000  shares
·Institutional: 22% (45% of float)
(35 institutions)
·Net Inst. Buying: 862.0K shares (+15.73%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
NeoTherapeutics, Inc. is a development-stage biopharmaceutical company engaged in the discovery and development of novel therapeutic drugs intended to treat neurological diseases such as memory deficits associated with Alzheimer's disease and aging, spinal cord injuries, Parkinson's disease and other neurodegenerative and psychiatric diseases. The Company has also become engaged in research involving functional genomics and the development of oncology drugs. The Company's lead product candidate, Neotrofin (AIT-082, leteprinim potassium), and other compounds under development, are based on its patented technology. This technology uses small synthetic molecules to create non-toxic compounds, intended to be administered orally or by injection, that are capable of passing through the blood-brain barrier to rapidly act upon specific target cells in specific locations in the central nervous system, including the brain.
More from Market Guide: Expanded Business Description

Financial Summary
NeoTherapeutics, Inc. is a development stage biopharmaceutical company engaged in the discovery and development of novel therapeutic drugs intended to treat neurodegenerative diseases and conditions. For the six months ended 6/30/01, revenue totaled $8 thousand, up from $0. Net loss decreased 44% to $12.1 million. Revenues reflect a licensing agreement with Pfizer. Lower loss reflects the termination of several contracts with outside clinical R&D groups.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Alvin Glasky, Ph.D., 67
Chairman, CEO, & Exec. Pres of NeoGene Technologies, Inc.
$1.1M
Rajesh Shrotriya M.D., 57
Pres, COO
110K
Samuel Gulko, 69
CFO, Sr. VP-Fin., Sec., Treasurer, Director
171K
Michelle Glasky, Ph.D., 41
VP- Scientific Affairs
140K
F. Jacob Huff, M.D., 52
VP, Clinical Affairs
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:NEOTAs of 31-Aug-2001
Price and Volume
52-Week Low
on 30-Jan-2001
$2.219
Recent Price$3.72 
52-Week High
on 31-Oct-2000
$10.00 
Beta0.92 
Daily Volume (3-month avg)67.3K
Daily Volume (10-day avg)70.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-51.2%
52-Week Change
relative to S&P500
-34.5%
Share-Related Items
Market Capitalization$77.3M
Shares Outstanding20.8M
Float10.2M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.52 
Earnings (ttm)-$2.87 
Earnings (mrq)-$0.36 
Sales (ttm)$0.00 
Cash (mrq)$0.90 
Valuation Ratios
Price/Book (mrq)7.12 
Price/EarningsN/A 
Price/Sales (ttm)6,662.06 
Income Statements
Sales (ttm)$8,000 
EBITDA (ttm)-$35.2M
Income available to common (ttm)-$36.9M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-173.55%
Return on Equity (ttm)-414.26%
Financial Strength
Current Ratio (mrq)4.71 
Debt/Equity (mrq)0.10 
Total Cash (mrq)$18.6M
Short Interest
As of 8-Aug-2001
Shares Short1.73M
Percent of Float17.0%
Shares Short
(Prior Month)
1.52M
Short Ratio26.68 
Daily Volume65.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.